The study introduces DreAM, a drug-inducible AAV system that enables tunable tissue-specific gene activation.

A recent article published in Nature Cardiovascular Research on June 13, 2025, details a groundbreaking study by Gabriele D’Uva from the University of Bologna.

This research underscores the necessity for flexible gene therapy options in regenerative medicine, especially in the context of cardiac regeneration.

DreAM has potential applications in treating myocardial infarction, a serious condition caused by heart tissue damage.

While AAV-based gene therapies show promise for treating various diseases, their long-lasting gene expression presents challenges for effective regenerative medicine.

The DreAM system employs the splicing modulator risdiplam as part of its gene activation mechanism.